Sonoma Pharmaceuticals (SNOA) Misses Q3 EPS by 43c

Sonoma Pharmaceuticals (NASDAQ: SNOA) reported Q3 EPS of ($0.48), $0.43 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $5.24 million.

For earnings history and earnings-related data on Sonoma Pharmaceuticals (SNOA) click here.

You May Also Be Interested In

• Barclays Starts DKSH Holding AG (DKSH:SW) at Overweight
• JPMorgan Starts Multi Commodity Exchange of India Ltd (MCX:IN) at Underweight
• Barclays Downgrades Telenor ASA (TEL:NO) (TELNY) to Underweight